Table 2.
The correlation between expression of SLP2 and clinical pathological features in external cohort.
| SLP2 | ||||
|---|---|---|---|---|
| Valuables | All cases (n = 90) |
Low expression (n = 38) (%) |
High expression (n = 52) (%) |
p value |
| Sex | 0.787 | |||
| Male | 53 | 23 (43.4) | 30 (56.6) | |
| Female | 37 | 15 (46.9) | 22 (53.1) | |
| Age | 0.501 | |||
| ≤62 | 44 | 17 (38.6) | 27 (61.4) | |
| >62 | 46 | 21 (45.7) | 25 (54.3) | |
| T Classification | 0.003 | |||
| T1+T2 | 14 | 11 (71.6) | 3 (28.4) | |
| T3+T4 | 76 | 27 (35.5) | 49 (64.5) | |
| Lymph node metastasis | 0.036 | |||
| Absent (N0) | 23 | 14 (60.9) | 9 (39.1) | |
| Present (N1-3) | 67 | 24 (35.8) | 43 (64.2) | |
| Distant metastasis | 0.476 | |||
| Absent (M0) | 86 | 37 (43.0) | 49 (57.0) | |
| Present (M1) | 4 | 1 (25.0) | 3 (75.0) | |
| AJCC stage | 0.037 | |||
| I+II | 36 | 20 (55.6) | 16 (44.4) | |
| III+IV | 54 | 18 (33.3) | 36 (66.7) | |